Study Summary
This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Targeted Activated DC combined with CAR-T therapy in patients with Advanced Solid Cancers.This combination therapy activates dendritic cells (DCs) to precisely target the tumor site, reshaping the tumor immune microenvironment, breaking down the immunosuppressive barrier, and allowing CAR-T cells to penetrate deeper into the tumor more efficiently, precisely and persistently killing cancer cells.
Want to learn more about this trial?
Request More InfoInterventions
Targeted Activated Dendritic CellsBIOLOGICAL
Autologous dendritic cells (DCs) genetically modified to express chimeric antigen receptor (CAR) and activation domain
Targeted CAR-T CellsBIOLOGICAL
Autologous T cells genetically modified to express chimeric antigen receptor (CAR)
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hainan Cancer Hospital | Haikou | Hainan | China |